Cell and gene therapies are advancing into late-stage development and commercialization, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny, inflating cost of goods, and causing delays that put timelines and patient access at risk.
By joining leading experts across quality, MSAT, supply chain, and process development, you will engage in face-to-face discussions on how peers are defining material specifications, managing lot-to-lot variability, and making critical qualification decisions under real development pressure.
Move on from theory and step inside the conversations shaping how raw material strategies are implemented in practice. Across technical case studies, peer-led discussions, and interactive workshops, you’ll explore how teams are managing suppliers, qualifying materials, overseeing supply chains, and navigating regulatory uncertainty in real-world settings.
Explore the 2026 Agenda to Discover:
- 19+ cross-functional experts spanning quality, MSAT, and supply chain shaping raw material strategies
- 2 in-depth workshops to deep dive into particulate risk and material transitions before they delay your programme
- Dedicated networking sessions & interactive roundtables designed to spark meaningful, problem-solving conversations
- Face-to-face access to peers and decision-makers to exchange practical experiences not captured in published reports
View the full program here to see the 19+ speaker faculty and full session details: https://ter.li/e0a0ldog